| (Values in U.S. Thousands) | Mar, 2025 | Dec, 2024 | Sep, 2024 | Jun, 2024 | Mar, 2024 |
| Sales | 10 | 30 | 0 | 20 | 0 |
| Sales Growth | -66.67% | unch | -100.00% | unch | unch |
| Net Income | -3,480 | -19,950 | -7,890 | -11,050 | -10,920 |
| Net Income Growth | +82.56% | -152.85% | +28.60% | -1.19% | -37.01% |
Eyenovia Inc
(EYEN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Eyenovia, Inc. is a clinical stage biopharmaceutical company which engages in developing therapeutics for the treatment of prominent eye diseases primarily in the United States. Its product portfolio includes MicroProst, MicroStat, MicroTears and MicroPine which are in clinical stage. Eyenovia, Inc. is based in New York.